Skip to main content
×
Home
    • Aa
    • Aa

Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies

  • Jenny Epstein (a1), Ian R. Sanderson (a1) and Thomas T. MacDonald (a1)
Abstract

Curcumin is the active ingredient of turmeric. It is widely used as a kitchen spice and food colorant throughout India, Asia and the Western world. Curcumin is a major constituent of curry powder, to which it imparts its characteristic yellow colour. For over 4000 years, curcumin has been used in traditional Asian and African medicine to treat a wide variety of ailments. There is a strong current public interest in naturally occurring plant-based remedies and dietary factors related to health and disease. Curcumin is non-toxic to human subjects at high doses. It is a complex molecule with multiple biological targets and different cellular effects. Recently, its molecular mechanisms of action have been extensively investigated. It has anti-inflammatory, antioxidant and anti-cancer properties. Under some circumstances its effects can be contradictory, with uncertain implications for human treatment. While more studies are warranted to further understand these contradictions, curcumin holds promise as a disease-modifying and chemopreventive agent. We review the evidence for the therapeutic potential of curcumin from in vitro studies, animal models and human clinical trials.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about sending content to Dropbox.

      Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about sending content to Google Drive.

      Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies
      Available formats
      ×
Copyright
Corresponding author
*Corresponding author: Jenny Epstein, fax +44 2078822187, email j.epstein@qmul.ac.uk
References
Hide All
1Anand P, Thomas SG, Kunnumakkara AB, et al. (2008) Biological activities of curcumin and its analogues (congeners) made by man and mother nature. Biochem Pharmacol 76, 15901611.
2Sandur SK, Pandey MK, Sung B, et al. (2007) Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and tumerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis 28, 17651773.
3Lao CD, Ruffin MTt, Normolle D, et al. (2006) Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 6, 10.
4Cheng AL, Hsu CH, Lin JK, et al. (2001) Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21, 28952900.
5Anand P, Kunnumakkara AB, Newman RA, et al. (2007) Bioavailability of curcumin: problems and promises. Mol Pharm 4, 807818.
6Sharma RA, Steward WP & Gescher AJ (2007) Pharmacokinetics and pharmacodynamics of curcumin. Adv Exp Med Biol 595, 453470.
7Pfeiffer E, Hoehle SI, Walch SG, et al. (2007) Curcuminoids form reactive glucuronides in vitro. J Agric Food Chem 55, 538544.
8Vareed SK, Kakarala M, Ruffin MT, et al. (2008) Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers 17, 14111417.
9Aggarwal BB & Harikumar KB (2009) Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 41, 4059.
10Pan M-H, Lin-Shiau S-Y & Lin J-K (2000) Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of IκB kinase and NF-κB activation in macrophages. Biochem Pharmacol 60, 16651676.
11Osawa T, Sugiyama Y, Inayoshi M, et al. (1995) Antioxidative activity of tetrahydrocurcuminoids. Biosci Biotechnol Biochem 59, 16091612.
12Naito M, Wu X, Nomura H, et al. (2002) The protective effects of tetrahydrocurcumin on oxidative stress in cholesterol-fed rabbits. J Atheroscler Thromb 9, 243250.
13Okada K, Wangpoengtrakul C, Tanaka T, et al. (2001) Curcumin and especially tetrahydrocurcumin ameliorate oxidative stress-induced renal injury in mice. J Nutr 131, 20902095.
14Sharma RA, Euden SA, Platton SL, et al. (2004) Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10, 68476854.
15Garcea G, Berry DP, Jones DJ, et al. (2005) Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 14, 120125.
16Ammon HP & Wahl MA (1991) Pharmacology of Curcuma longa. Planta Med 57, 17.
17Strimpakos AS & Sharma RA (2008) Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 10, 511545.
18Kurien BT, Singh A, Matsumoto H, et al. (2007) Improving the solubility and pharmacological efficacy of curcumin by heat treatment. Assay Drug Dev Technol 5, 567576.
19National Toxicology Program (1993) NTP Toxicology and Carcinogenesis Studies of Turmeric Oleoresin (CAS No. 8024-37-1) (Major Component 79 %–85 % Curcumin, CAS No. 458-37-7) in F344/N Rats and B6C3F1 Mice (Feed Studies). Natl Toxicol Program Tech Rep Ser 427, 1275.
20Somasundaram S, Edmund NA, Moore DT, et al. (2002) Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res 62, 38683875.
21Sandur SK, Ichikawa H, Pandey MK, et al. (2007) Role of pro-oxidants and antioxidants in the anti-inflammatory and apoptotic effects of curcumin (diferuloylmethane). Free Radic Biol Med 43, 568580.
22Chainani-Wu N (2003) Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med 9, 161168.
23Singh S & Aggarwal BB (1995) Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 270, 2499525000.
24Aggarwal S, Ichikawa H, Takada Y, et al. (2006) Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol 69, 195206.
25Shishodia S, Amin HM, Lai R, et al. (2005) Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 70, 700713.
26Aggarwal BB, Sethi G, Ahn KS, et al. (2006) Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci 1091, 151169.
27Bharti AC, Donato N & Aggarwal BB (2003) Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 171, 38633871.
28Mackenzie GG, Queisser N, Wolfson ML, et al. (2008) Curcumin induces cell-arrest and apoptosis in association with the inhibition of constitutively active NF-kappaB and STAT3 pathways in Hodgkin's lymphoma cells. Int J Cancer 123, 5665.
29Han SS, Chung ST, Robertson DA, et al. (1999) Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-kappa B, and p53. Clin Immunol 93, 152161.
30Fujio Y, Kunisada K, Hirota H, et al. (1997) Signals through gp130 upregulate bcl-x gene expression via STAT1-binding cis-element in cardiac myocytes. J Clin Invest 99, 28982905.
31Sinibaldi D, Wharton W, Turkson J, et al. (2000) Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene 19, 54195427.
32Sarraf P, Mueller E, Smith WM, et al. (1999) Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell 3, 799804.
33Nakamura YK & Omaye ST (2009) Conjugated linoleic acid isomers' roles in the regulation of PPAR-gamma and NF-kappaB DNA binding and subsequent expression of antioxidant enzymes in human umbilical vein endothelial cells. Nutrition 25, 800811.
34Ondrey F (2009) Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention. Clin Cancer Res 15, 28.
35Xu J, Fu Y & Chen A (2003) Activation of peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth. Am J Physiol 285, G20G30.
36Chen A & Xu J (2005) Activation of PPAR{gamma} by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. Am J Physiol 288, G447G456.
37Wetzker R & Bohmer FD (2003) Transactivation joins multiple tracks to the ERK/MAPK cascade. Nat Rev Mol Cell Biol 4, 651657.
38Binion DG, Otterson MF & Rafiee P (2008) Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut 57, 15091517.
39Chen YR & Tan TH (1998) Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene 17, 173178.
40Collett GP & Campbell FC (2004) Curcumin induces c-jun N-terminal kinase-dependent apoptosis in HCT116 human colon cancer cells. Carcinogenesis 25, 21832189.
41Hu M, Du Q, Vancurova I, et al. (2005) Proapoptotic effect of curcumin on human neutrophils: activation of the p38 mitogen-activated protein kinase pathway. Crit Care Med 33, 25712578.
42Moos PJ, Edes K, Mullally JE, et al. (2004) Curcumin impairs tumor suppressor p53 function in colon cancer cells. Carcinogenesis 25, 16111617.
43Tsvetkov P, Asher G, Reiss V, et al. (2005) Inhibition of NAD(P)H:quinone oxidoreductase 1 activity and induction of p53 degradation by the natural phenolic compound curcumin. Proc Natl Acad Sci U S A 102, 55355540.
44Choudhuri T, Pal S, Das T, et al. (2005) Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem 280, 2005920068.
45Song G, Mao YB, Cai QF, et al. (2005) Curcumin induces human HT-29 colon adenocarcinoma cell apoptosis by activating p53 and regulating apoptosis-related protein expression. Braz J Med Biol Res 38, 17911798.
46Fisher B, Costantino JP, Wickerham DL, et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90, 13711388.
47Arbiser JL, Klauber N, Rohan R, et al. (1998) Curcumin is an in vivo inhibitor of angiogenesis. Mol Med 4, 376383.
48Thaloor D, Singh AK, Sidhu GS, et al. (1998) Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curcumin. Cell Growth Differ 9, 305312.
49Bae MK, Kim SH, Jeong JW, et al. (2006) Curcumin inhibits hypoxia-induced angiogenesis via down-regulation of HIF-1. Oncol Rep 15, 15571562.
50Shim JS, Kim JH, Cho HY, et al. (2003) Irreversible inhibition of CD13/aminopeptidase N by the antiangiogenic agent curcumin. Chem Biol 10, 695704.
51Pasqualini R, Koivunen E, Kain R, et al. (2000) Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 60, 722727.
52Rafiee P, Nelson VM, Manley S, et al. (2009) Effect of curcumin on acidic pH-induced expression of IL-6 and IL-8 in human esophageal epithelial cells (HET-1A): role of PKC, MAPKs, and NF-kappaB. Am J Physiol 296, G388G398.
53Cohen AN, Veena MS, Srivatsan ES, et al. (2009) Suppression of interleukin 6 and 8 production in head and neck cancer cells with curcumin via inhibition of Ikappa beta kinase. Arch Otolaryngol Head Neck Surg 135, 190197.
54Nishisho I, Nakamura Y, Miyoshi Y, et al. (1991) Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 253, 665669.
55Thun MJ, Namboodiri MM & Heath CW Jr (1991) Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325, 15931596.
56Plummer SM, Holloway KA, Manson MM, et al. (1999) Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene 18, 60136020.
57Pender SL & MacDonald TT (2004) Matrix metalloproteinases and the gut – new roles for old enzymes. Curr Opin Pharmacol 4, 546550.
58Vihinen P, Ala-aho R & Kahari VM (2005) Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 5, 203220.
59Yodkeeree S, Garbisa S & Limtrakul P (2008) Tetrahydrocurcumin inhibits HT1080 cell migration and invasion via downregulation of MMPs and uPA. Acta Pharmacol Sin 29, 853860.
60Saja K, Babu MS, Karunagaran D, et al. (2007) Anti-inflammatory effect of curcumin involves downregulation of MMP-9 in blood mononuclear cells. Int Immunopharmacol 7, 16591667.
61Claramunt RM, Bouissane L, Cabildo MP, et al. (2009) Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloproteinases. Bioorg Med Chem 17, 12901296.
62Epstein J, Docena G, MacDonald TT, et al. (2010) Curcumin suppresses p38 mitogen-activated protein kinase activation, reduces IL-1 beta and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of children and adults with inflammatory bowel disease. Br J Nutr 103, 824832.
63Lee CW, Lin WN, Lin CC, et al. (2006) Transcriptional regulation of VCAM-1 expression by tumor necrosis factor-alpha in human tracheal smooth muscle cells: involvement of MAPKs, NF-kappaB, p300, and histone acetylation. J Cell Physiol 207, 174186.
64Balasubramanyam K, Varier RA, Altaf M, et al. (2004) Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 279, 5116351171.
65Roth SY, Denu JM & Allis CD (2001) Histone acetyltransferases. Annu Rev Biochem 70, 81120.
66Sanderson IR & Naik S (2000) Dietary regulation of intestinal gene expression. Annu Rev Nutr 20, 311338.
67Monteleone G, Del Vecchio Blanco G, Monteleone I, et al. (2005) Post-transcriptional regulation of Smad7 in the gut of patients with inflammatory bowel disease. Gastroenterology 129, 14201429.
68Ongeri EM, Verderame MF & Hammond JM (2005) Follicle-stimulating hormone induction of ovarian insulin-like growth factor-binding protein-3 transcription requires a TATA box-binding protein and the protein kinase A and phosphatidylinositol-3 kinase pathways. Mol Endocrinol 19, 18371848.
69White NR, Mulligan P, King PJ, et al. (2006) Sodium butyrate-mediated Sp3 acetylation represses human insulin-like growth factor binding protein-3 expression in intestinal epithelial cells. J Pediatr Gastroenterol Nutr 42, 134141.
70Yang XJ (2004) The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res 32, 959976.
71Brooks CL & Gu W (2003) Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 15, 164171.
72Muraoka M, Konishi M, Kikuchi-Yanoshita R, et al. (1996) p300 Gene alterations in colorectal and gastric carcinomas. Oncogene 12, 15651569.
73Chen Y, Shu W, Chen W, et al. (2007) Curcumin, both histone deacetylase and p300/CBP-specific inhibitor, represses the activity of nuclear factor kappa B and Notch 1 in Raji cells. Basic Clin Pharmacol Toxicol 101, 427433.
74Heuschkel RB, Menache CC, Megerian JT, et al. (2000) Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. J Pediatr Gastroenterol Nutr 31, 815.
75Bannerjee K, Camacho-Hubner C, Babinska K, et al. (2004) Anti-inflammatory and growth-stimulating effects precede nutritional restitution during enteral feeding in Crohn disease. J Pediatr Gastroenterol Nutr 38, 270275.
76Goh K & Xiao SD (2009) Inflammatory bowel disease: a survey of the epidemiology in Asia. J Dig Dis 10, 16.
77Montgomery SM, Morris DL, Pounder RE, et al. (1999) Asian ethnic origin and the risk of inflammatory bowel disease. Eur J Gastroenterol Hepatol 11, 543546.
78Jian YT, Mai GF, Wang JD, et al. (2005) Preventive and therapeutic effects of NF-kappaB inhibitor curcumin in rats colitis induced by trinitrobenzene sulfonic acid. World J Gastroenterol 11, 17471752.
79Sugimoto K, Hanai H, Tozawa K, et al. (2002) Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology 123, 19121922.
80Nones K, Knoch B, Dommels YE, et al. (2009) Multidrug resistance gene deficient (mdr1a( − / − )) mice have an altered caecal microbiota that precedes the onset of intestinal inflammation. J Appl Microbiol 107, 557566.
81Venkataranganna MV, Rafiq M, Gopumadhavan S, et al. (2007) NCB-02 (standardized Curcumin preparation) protects dinitrochlorobenzene- induced colitis through down-regulation of NFkappa-B and iNOS. World J Gastroenterol 13, 11031107.
82Billerey-Larmonier C, Uno JK, Larmonier N, et al. (2008) Protective effects of dietary curcumin in mouse model of chemically induced colitis are strain dependent. Inflamm Bowel Dis 14, 780793.
83Larmonier CB, Uno JK, Lee KM, et al. (2008) Limited effects of dietary curcumin on Th-1 driven colitis in IL-10 deficient mice suggest an IL-10-dependent mechanism of protection. Am J Physiol 295, G1079G1091.
84Rao CV, Simi B & Reddy BS (1993) Inhibition by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon. Carcinogenesis 14, 22192225.
85Kim JM, Araki S, Kim DJ, et al. (1998) Chemopreventive effects of carotenoids and curcumins on mouse colon carcinogenesis after 1,2-dimethylhydrazine initiation. Carcinogenesis 19, 8185.
86Ushida J, Sugie S, Kawabata K, et al. (2000) Chemopreventive effect of curcumin on N-nitrosomethylbenzylamine-induced esophageal carcinogenesis in rats. Jpn J Cancer Res 91, 893898.
87Ikezaki S, Nishikawa A, Furukawa F, et al. (2001) Chemopreventive effects of curcumin on glandular stomach carcinogenesis induced by N-methyl-N′-nitro-N-nitrosoguanidine and sodium chloride in rats. Anticancer Res 21, 34073411.
88Chuang SE, Cheng AL, Lin JK, et al. (2000) Inhibition by curcumin of diethylnitrosamine-induced hepatic hyperplasia, inflammation, cellular gene products and cell-cycle-related proteins in rats. Food Chem Toxicol 38, 991995.
89Azuine MA & Bhide SV (1992) Protective single/combined treatment with betel leaf and turmeric against methyl (acetoxymethyl) nitrosamine-induced hamster oral carcinogenesis. Int J Cancer 51, 412415.
90Huang MT, Lou YR, Xie JG, et al. (1998) Effect of dietary curcumin and dibenzoylmethane on formation of 7,12-dimethylbenz[a]anthracene-induced mammary tumors and lymphomas/leukemias in Sencar mice. Carcinogenesis 19, 16971700.
91Hecht SS, Kenney PM, Wang M, et al. (1999) Evaluation of butylated hydroxyanisole, myo-inositol, curcumin, esculetin, resveratrol and lycopene as inhibitors of benzo[a]pyrene plus 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in A/J mice. Cancer Lett 137, 123130.
92Okazaki Y, Iqbal M & Okada S (2005) Suppressive effects of dietary curcumin on the increased activity of renal ornithine decarboxylase in mice treated with a renal carcinogen, ferric nitrilotriacetate. Biochim Biophys Acta 1740, 357366.
93Sindhwani P, Hampton JA, Baig MM, et al. (2001) Curcumin prevents intravesical tumor implantation of the MBT-2 tumor cell line in C3H mice. J Urol 166, 14981501.
94Limtrakul P, Lipigorngoson S, Namwong O, et al. (1997) Inhibitory effect of dietary curcumin on skin carcinogenesis in mice. Cancer Lett 116, 197203.
95Kuttan R, Bhanumathy P, Nirmala K, et al. (1985) Potential anticancer activity of turmeric (Curcuma longa). Cancer Lett 29, 197202.
96Odot J, Albert P, Carlier A, et al. (2004) In vitro and in vivo anti-tumoral effect of curcumin against melanoma cells. Int J Cancer 111, 381387.
97LoTempio MM, Veena MS, Steele HL, et al. (2005) Curcumin suppresses growth of head and neck squamous cell carcinoma. Clin Cancer Res 11, (19 Pt 1), 69947002.
98Dorai T, Cao YC, Dorai B, et al. (2001) Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate 47, 293303.
99Kunnumakkara AB, Guha S, Krishnan S, et al. (2007) Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67, 38533861.
100Li L, Braiteh FS & Kurzrock R (2005) Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 104, 13221331.
101Li L, Ahmed B, Mehta K, et al. (2007) Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther 6, 12761282.
102Ohashi Y, Tsuchiya Y, Koizumi K, et al. (2003) Prevention of intrahepatic metastasis by curcumin in an orthotopic implantation model. Oncology 65, 250258.
103Aggarwal BB, Shishodia S, Takada Y, et al. (2005) Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 11, 74907498.
104Bachmeier B, Nerlich AG, Iancu CM, et al. (2007) The chemopreventive polyphenol curcumin prevents hematogenous breast cancer metastases in immunodeficient mice. Cell Physiol Biochem 19, 137152.
105Lin YG, Kunnumakkara AB, Nair A, et al. (2007) Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res 13, 34233430.
106Kobelt G (2006) Health economic issues in rheumatoid arthritis. Scand J Rheumatol 35, 415425.
107Deodhar SD, Sethi R & Srimal RC (1980) Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J Med Res 71, 632634.
108Heng MC, Song MK, Harker J, et al. (2000) Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters. Br J Dermatol 143, 937949.
109Satoskar RR, Shah SJ & Shenoy SG (1986) Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. Int J Clin Pharmacol Ther Toxicol 24, 651654.
110Lal B, Kapoor AK, Agrawal PK, et al. (2000) Role of curcumin in idiopathic inflammatory orbital pseudotumours. Phytother Res 14, 443447.
111Lal B, Kapoor AK, Asthana OP, et al. (1999) Efficacy of curcumin in the management of chronic anterior uveitis. Phytother Res 13, 318322.
112Bundy R, Walker AF, Middleton RW, et al. (2004) Turmeric extract may improve irritable bowel syndrome symptomology in otherwise healthy adults: a pilot study. J Altern Complement Med 10, 10151018.
113Durgaprasad S, Pai CG & Vasanthkumar (2005) A pilot study of the antioxidant effect of curcumin in tropical pancreatitis. Indian J Med Res 122, 315318.
114Niederau C & Gopfert E (1999) The effect of chelidonium- and turmeric root extract on upper abdominal pain due to functional disorders of the biliary system. Results from a placebo-controlled double-blind study. Med Klin (Munich) 94, 425430.
115Rasyid A & Lelo A (1999) The effect of curcumin and placebo on human gall-bladder function: an ultrasound study. Aliment Pharmacol Ther 13, 245249.
116Rasyid A, Rahman AR, Jaalam K, et al. (2002) Effect of different curcumin dosages on human gall bladder. Asia Pac J Clin Nutr 11, 314318.
117Prucksunand C, Indrasukhsri B, Leethochawalit M, et al. (2001) Phase II clinical trial on effect of the long turmeric (Curcuma longa Linn) on healing of peptic ulcer. Southeast Asian J Trop Med Public Health 32, 208215.
118Cruz-Correa M, Shoskes DA, Sanchez P, et al. (2006) Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 4, 10351038.
119Soni KB & Kuttan R (1992) Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J Physiol Pharmacol 36, 273275.
120Usharani P, Mateen AA, Naidu MU, et al. (2008) Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study. Drugs R D 9, 243250.
121Shoskes D, Lapierre C, Cruz-Correa M, et al. (2005) Beneficial effects of the bioflavonoids curcumin and quercetin on early function in cadaveric renal transplantation: a randomized placebo controlled trial. Transplantation 80, 15561559.
122Holt PR, Katz S & Kirshoff R (2005) Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci 50, 21912193.
123Hanai H, Iida T, Takeuchi K, et al. (2006) Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 4, 15021506.
124Sharma RA, McLelland HR, Hill KA, et al. (2001) Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 7, 18941900.
125Kuttan R, Sudheeran PC & Josph CD (1987) Turmeric and curcumin as topical agents in cancer therapy. Tumori 73, 2931.
126Dhillon N, Aggarwal BB, Newman RA, et al. (2008) Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14, 44914499.
127Baum L, Lam CW, Cheung SK, et al. (2008) Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 28, 110113.
128Liang G, Zhou H, Wang Y, et al. (2009) Inhibition of LPS-induced production of inflammatory factors in the macrophages by mono-carbonyl analogues of Curcumin. J Cell Mol Med.
129Weber WM, Hunsaker LA, Gonzales AM, et al. (2006) TPA-induced up-regulation of activator protein-1 can be inhibited or enhanced by analogs of the natural product curcumin. Biochem Pharmacol 72, 928940.
130Olszanecki R, Gebska A & Korbut R (2007) The role of haem oxygenase-1 in the decrease of endothelial intercellular adhesion molecule-1 expression by curcumin. Basic Clin Pharmacol Toxicol 101, 411415.
131Srinivasan M, Rajendra Prasad N & Menon VP (2006) Protective effect of curcumin on gamma-radiation induced DNA damage and lipid peroxidation in cultured human lymphocytes. Mutat Res 611, 96103.
132Balogun E, Hoque M, Gong P, et al. (2003) Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem J 371 (Pt 3), 887895.
133Liao YF, Hung HC, Hour TC, et al. (2008) Curcumin induces apoptosis through an ornithine decarboxylase-dependent pathway in human promyelocytic leukemia HL-60 cells. Life Sci 82, 367375.
134Wang JB, Qi LL, Zheng SD, et al. (2009) Curcumin induces apoptosis through the mitochondria-mediated apoptotic pathway in HT-29 cells. J Zhejiang Univ Sci 10, 93102.
135Hussain AR, Al-Rasheed M, Manogaran PS, et al. (2006) Curcumin induces apoptosis via inhibition of PI3′-kinase/AKT pathway in acute T cell leukemias. Apoptosis 11, 245254.
136Liu JY, Lin SJ & Lin JK (1993) Inhibitory effects of curcumin on protein kinase C activity induced by 12-O-tetradecanoyl-phorbol-13-acetate in NIH 3T3 cells. Carcinogenesis 14, 857861.
137Pendurthi UR & Rao LV (2000) Suppression of transcription factor Egr-1 by curcumin. Thromb Res 97, 179189.
138Huang MT, Lou YR, Ma W, et al. (1994) Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res 54, 58415847.
139Collett GP, Robson CN, Mathers JC, et al. (2001) Curcumin modifies Apc(min) apoptosis resistance and inhibits 2-amino 1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) induced tumour formation in Apc(min) mice. Carcinogenesis 22, 821825.
140Rao CV, Rivenson A, Simi B, et al. (1995) Chemoprevention of colon cancer by dietary curcumin. Ann N Y Acad Sci 768, 201204.
141Kawamori T, Lubet R, Steele VE, et al. (1999) Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res 59, 597601.
142Pereira MA, Grubbs CJ, Barnes LH, et al. (1996) Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane-induced colon cancer and 7,12-dimethylbenz[a]anthracene-induced mammary cancer in rats. Carcinogenesis 17, 13051311.
143Kwon Y, Malik M & Magnuson BA (2004) Inhibition of colonic aberrant crypt foci by curcumin in rats is affected by age. Nutr Cancer 48, 3743.
144Shpitz B, Giladi N, Sagiv E, et al. (2006) Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model. Digestion 74, 140144.
145Volate SR, Davenport DM, Muga SJ, et al. (2005) Modulation of aberrant crypt foci and apoptosis by dietary herbal supplements (quercetin, curcumin, silymarin, ginseng and rutin). Carcinogenesis 26, 14501456.
146Kwon Y & Magnuson BA (2007) Effect of azoxymethane and curcumin on transcriptional levels of cyclooxygenase-1 and -2 during initiation of colon carcinogenesis. Scand J Gastroenterol 42, 7280.
147Devasena T, Menon VP & Rajasekharan KN (2006) Prevention of 1,2-dimethylhydrazine-induced circulatory oxidative stress by bis-1,7-(2-hydroxyphenyl)-hepta-1,6-diene-3,5-dione during colon carcinogenesis. Pharmacol Rep 58, 229235.
148Xu G, Huang W, Zhang WM, et al. (2005) Effects of combined use of curcumin and catechin on cyclooxygenase-2 mRNA expression in dimethylhydrazine-induced rat colon carcinogenesis. Di Yi Jun Yi Da Xue Xue Bao 25, 4852.
149Kim SJ & Hellerstein MK (2007) Pharmacological doses of dietary curcumin increase colon epithelial cell proliferation in vivo in rats. Phytother Res 21, 995998.
150Azuine MA & Bhide SV (1992) Chemopreventive effect of turmeric against stomach and skin tumors induced by chemical carcinogens in Swiss mice. Nutr Cancer 17, 7783.
151Singh SV, Hu X, Srivastava SK, et al. (1998) Mechanism of inhibition of benzo[a]pyrene-induced forestomach cancer in mice by dietary curcumin. Carcinogenesis 19, 13571360.
152Nagabhushan M & Bhide SV (1992) Curcumin as an inhibitor of cancer. J Am Coll Nutr 11, 192198.
153Swamy MV, Citineni B, Patlolla JM, et al. (2008) Prevention and treatment of pancreatic cancer by curcumin in combination with omega-3 fatty acids. Nutr Cancer 60, Suppl. 1, 8189.
154Tanaka T, Makita H, Ohnishi M, et al. (1994) Chemoprevention of 4-nitroquinoline 1-oxide-induced oral carcinogenesis by dietary curcumin and hesperidin: comparison with the protective effect of beta-carotene. Cancer Res 54, 46534659.
155Lin CC, Lu YP, Lou YR, et al. (2001) Inhibition by dietary dibenzoylmethane of mammary gland proliferation, formation of DMBA-DNA adducts in mammary glands, and mammary tumorigenesis in Sencar mice. Cancer Lett 168, 125132.
156Singletary K, MacDonald C, Wallig M, et al. (1996) Inhibition of 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumorigenesis and DMBA-DNA adduct formation by curcumin. Cancer Lett 103, 137141.
157Deshpande SS, Ingle AD & Maru GB (1998) Chemopreventive efficacy of curcumin-free aqueous turmeric extract in 7,12-dimethylbenz[a]anthracene-induced rat mammary tumorigenesis. Cancer Lett 123, 3540.
158Inano H & Onoda M (2002) Radioprotective action of curcumin extracted from Curcuma longa LINN: inhibitory effect on formation of urinary 8-hydroxy-2′-deoxyguanosine, tumorigenesis, but not mortality, induced by gamma-ray irradiation. Int J Radiat Oncol Biol Phys 53, 735743.
159Inano H, Onoda M, Inafuku N, et al. (1999) Chemoprevention by curcumin during the promotion stage of tumorigenesis of mammary gland in rats irradiated with gamma-rays. Carcinogenesis 20, 10111018.
160Lin CC, Ho CT & Huang MT (2001) Mechanistic studies on the inhibitory action of dietary dibenzoylmethane, a beta-diketone analogue of curcumin, on 7,12-dimethylbenz[a]anthracene-induced mammary tumorigenesis. Proc Natl Sci Counc Repub China 25, 158165.
161Ishizaki C, Oguro T, Yoshida T, et al. (1996) Enhancing effect of ultraviolet A on ornithine decarboxylase induction and dermatitis evoked by 12-O-tetradecanoylphorbol-13-acetate and its inhibition by curcumin in mouse skin. Dermatology 193, 311317.
162Huang MT, Smart RC, Wong CQ, et al. (1988) Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 48, 59415946.
163Lu YP, Chang RL, Huang MT, et al. (1993) Inhibitory effect of curcumin on 12-O-tetradecanoylphorbol-13-acetate-induced increase in ornithine decarboxylase mRNA in mouse epidermis. Carcinogenesis 14, 293297.
164Huang MT, Ma W, Lu YP, et al. (1995) Effects of curcumin, demethoxycurcumin, bisdemethoxycurcumin and tetrahydrocurcumin on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion. Carcinogenesis 16, 24932497.
165Huang MT, Ma W, Yen P, et al. (1997) Inhibitory effects of topical application of low doses of curcumin on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion and oxidized DNA bases in mouse epidermis. Carcinogenesis 18, 8388.
166Soudamini KK & Kuttan R (1989) Inhibition of chemical carcinogenesis by curcumin. J Ethnopharmacol 27, 227233.
167Huang MT, Deschner EE, Newmark HL, et al. (1992) Effect of dietary curcumin and ascorbyl palmitate on azoxymethanol-induced colonic epithelial cell proliferation and focal areas of dysplasia. Cancer Lett 64, 117121.
168William BM, Goodrich A, Peng C, et al. (2008) Curcumin inhibits proliferation and induces apoptosis of leukemic cells expressing wild-type or T315I-BCR-ABL and prolongs survival of mice with acute lymphoblastic leukemia. Hematology 13, 333343.
169Sung B, Kunnumakkara AB, Sethi G, et al. (2009) Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther 8, 959970.
170Iqbal M, Okazaki Y & Okada S (2009) Curcumin attenuates oxidative damage in animals treated with a renal carcinogen, ferric nitrilotriacetate (Fe-NTA): implications for cancer prevention. Mol Cell Biochem 324, 157164.
171Purkayastha S, Berliner A, Fernando SS, et al. (2009) Curcumin blocks brain tumor formation. Brain Res.
172Narayanan NK, Nargi D, Randolph C, et al. (2009) Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int J Cancer 125, 18.
173Manoharan S, Balakrishnan S, Menon VP, et al. (2009) Chemopreventive efficacy of curcumin and piperine during 7,12-dimethylbenz[a]anthracene-induced hamster buccal pouch carcinogenesis. Singapore Med J 50, 139146.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

British Journal of Nutrition
  • ISSN: 0007-1145
  • EISSN: 1475-2662
  • URL: /core/journals/british-journal-of-nutrition
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 283
Total number of PDF views: 1287 *
Loading metrics...

Abstract views

Total abstract views: 1533 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 21st October 2017. This data will be updated every 24 hours.